Bharat Parenterals gets DCGI nod for Favipiravir oral suspension

Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of Covid-19 patients.

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.

Related Posts

Over-the-counter sale of cough syrup barred

Following the Drugs Rules amendment, lozenges, pills, and tablets for cough will still be available over the counter; 24 children in M.P. died after consuming adulterated cough syrup last year…

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

Mumbai: On Tuesday, the FDA said it had sealed a cosmetic manufacturing factory in Bhiwandi for allegedly misleading consumers on e-commerce platforms by labelling its products as sulfate-free and paraben-free. The stock…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Over-the-counter sale of cough syrup barred

Over-the-counter sale of cough syrup barred

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

FDA seals Bhiwandi-based cosmetic factory for misleading claims, fake address

Yashoda Medicity’s AI-enabled E- ICU poised to make Quality Critical Care Universal

Yashoda Medicity’s AI-enabled E- ICU poised to make Quality Critical Care Universal

Licences no shield in NDPS cases: HC refuses bail in 1.37 crore tablets seizure

Licences no shield in NDPS cases: HC refuses bail in 1.37 crore tablets seizure

No cough syrups without a doctor’s prescription – New rules announced

No cough syrups without a doctor’s prescription – New rules announced

CSIR-IIIM launches two-month certificate course On cGMP-compliant herbal drug manufacturing

CSIR-IIIM launches two-month certificate course On cGMP-compliant herbal drug manufacturing